Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

lemborexant

lemborexant
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
DayVigo TABLET, ORAL 5 mg, 10 mg    
Comments:

Defer initiation to outpatient setting. If lemborexant is ordered while inpatient, it will be interchanged to zolpidem according to the table below. If lemborexant is ordered for continuation of a home medication, it will be interchanged to Belsomra according to the table below or the patient may use their home supply.

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

lemborexant (DayVigo)

  • 5 mg
  • 10 mg

zolpidem (Ambien)

  • 5 mg
  • 10 mg (5 mg if female)

lemborexant (DayVigo)

  • 5 mg (continuation of home med)
  • 10 mg (continuation of home med)

suvorexant (Belsomra)

  • 5 mg
  • 15 mg

Reviewed: October 2020 (DayVigo)

Last updated: Nov. 2, 2020






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved